Literature DB >> 20689293

Outcome after resection of one hundred gastrointestinal stromal tumors.

K Krajinovic1, C T Germer, A Agaimy, P H Wünsch, C Isbert.   

Abstract

AIMS: To evaluate the outcome after surgical resection in patients with gastrointestinal stromal tumors and to determine the factors influencing local tumor recurrence or distant metastatic disease after locally complete tumor resection (R0).
METHODS: Outcomes of 100 patients with primary gastrointestinal stromal tumors (GIST) surgically managed between 1997 and 2006 at a single institution were reviewed. Univariate and bivariate analyses were used to determine factors affecting recurrence-free and tumor-free survival.
RESULTS: All patients (n = 100) had c-kit-positive GIST. There were 17% (n = 17) very low risk, 41% (n = 41) low risk, 19% (n = 19) intermediate risk and 23% (n = 23) high risk GIST originating from the stomach, small bowel, colon and rectum. The median patient age was 68 years (range 39-92). Seventy-three percent of the patients had symptomatic local disease. Most (94%; n = 94) of them underwent R0 resections of their primary tumor. R0 resection was significantly associated with a lower tumor-related mortality rate (p = 0.0001). The patients with recurrence/metastases had significantly larger tumors (p = 0.0017) and a mitotic index higher than 5/50 HPF (p = 0.0001). Seven of 20 patients from the high-risk group and 2 of 7 patients with metastatic disease developed local recurrence or further metastatatic tumor spread following R0 resection.
CONCLUSION: Surgical removal continues to be the mainstay of GIST treatment. R0 resection, tumor size and mitotic index are significant prognostic factors. Overall, more than 30% of the patients with high-risk GIST develop local recurrences and distant metastases despite R0 resection. Additional molecular pathological markers are needed to yield a more accurate tumor profile and to thus achieve a better predictability of the biological behavior of GIST. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20689293     DOI: 10.1159/000280022

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  8 in total

1.  MiR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor.

Authors:  Sheng Liu; Juan Cui; Guoqing Liao; Yi Zhang; Ke Ye; Tailiang Lu; Jing Qi; Guohui Wan
Journal:  Tumour Biol       Date:  2014-06-12

2.  Prognostic factors and outcome of resected patients with gastrointestinal stromal tumors of small intestine.

Authors:  Rong Fan; Jie Zhong; Zhen-ting Wang; Li-fen Yu; Yong-hua Tang; Wei-guo Hu; Yan-bo Zhu; Xiao-long Jin
Journal:  Med Oncol       Date:  2010-10-08       Impact factor: 3.064

3.  Duodenal GIST: a single center experience.

Authors:  Alexander Beham; Inga-Marie Schaefer; Silke Cameron; Katharina von Hammerstein; Laszlo Füzesi; Giuliano Ramadori; Michael B Ghadimi
Journal:  Int J Colorectal Dis       Date:  2012-02-22       Impact factor: 2.571

4.  Recurring gastrointestinal stromal tumor with splenic metastasis.

Authors:  Ho Gun Kim; Seong Yeob Ryu; Jae Kyoon Joo; Hyo Kang; Jae Hyuk Lee; Dong Yi Kim
Journal:  J Korean Surg Soc       Date:  2011-11-25

5.  Wide Surgical Margin Improves the Outcome for Patients with Gastrointestinal Stromal Tumors (GISTs).

Authors:  Jan Åhlén; Fredrik Karlsson; Johan Wejde; Inga-Lena Nilsson; Catharina Larsson; Robert Bränström
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

6.  A Retrospective Study of Postoperative Outcomes in 98 Patients Diagnosed with Gastrointestinal Stromal Tumor (GIST) of the Upper, Middle, and Lower Gastrointestinal Tract Between 2009 and 2019 at a Single Center in Poland.

Authors:  Patryk Zemła; Anna Stelmach; Beata Jabłońska; Dariusz Gołka; Sławomir Mrowiec
Journal:  Med Sci Monit       Date:  2021-10-14

7.  Preoperative predictors of malignant gastric submucosal tumor.

Authors:  Ho Goon Kim; Seong Yeob Ryu; Sang Kwon Yun; Jae Kyoon Joo; Jae Hyuk Lee; Dong Yi Kim
Journal:  J Korean Surg Soc       Date:  2012-07-25

8.  Discordant Primary Resistance to Imatinib Mesylate in the Same Individual and Splenic Involvement in Recurring Gastric Gastrointestinal Stromal Tumors: Assessment by Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography.

Authors:  Preeti Fargose; Sandip Basu
Journal:  Indian J Nucl Med       Date:  2018 Apr-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.